Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
Adhering to mucormycosis treatment guidelines may be difficult for physicians because of the complexity of the disease.
Researchers found no evidence that neutropenic and non-neutropenic patients with sepsis should be treated differently.
Vancomycin-resistant Enterococcus bacteremia was associated with poorer outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Risk for developing active tuberculosis has not been previously assessed in patients undergoing hematopoietic cell transplantation.
Sirolimus treatment of patients undergoing allogeneic hematopoietic stem cell transplantation may prevent cytomegalovirus infection.
The risk factors of human rhinovirus lower respiratory tract infection following hematopoietic cell transplantation are not well known.
Researchers assessed risk factors for cytomegalovirus antigenemia in pediatric patients.
Patients undergoing autologous stem cell transplant are at increased risk for central line-associated bloodstream infections.
Researchers assessed a possible association between plateletpheresis and lymphopenia when 2 platelet donors were found to have low CD4+ T-lymphocyte counts.
A single-allele mismatch was associated with decreased risk of non-relapse mortality and overall mortality compared with a single-antigen mismatch.
Though patients tended to be older at diagnosis, the severity of genetic hemochromatosis has decreased over time.
The prognostic value of karyotype in systemic mastocytosis, especially in the presence of adverse mutations, is unclear.
Kawasaki is a rare hematologic disease that occurs in fewer than 20,000 patients in the United States annually.
The combination of the 2 drugs seems to display synergistic effects.
In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.
Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.
A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.
Amneal’s generic product is available in a 5mg strength tablet supplied in 100-count bottles.
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.
Researchers evaluated whether pacritinib would improve SVR and TSS compared with the best available therapy, including ruxolitinib.
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.
Researchers examined the effect of riociguat compared with placebo on the REVEAL risk score and long-term outcomes for pulmonary arterial hypertension.
Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety.
Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.
This is the first-ever drug approval for the blood cancer, which, although rare, carries a poor prognosis.
Researchers compared the safety and efficacy of ruxolitinib vs momelotinib, a selective JAK1/2 inhibitor, among JAK inhibitor-naïve patients with myelofibrosis.
The FDA expanded the indications of ibrutinib to include the treatment of adult patients with cGVHD who have failed at least one prior therapy.
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.
Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.
BRAF other MAPK pathway gene mutations associated with Erdheim-Chester disease reveal that ECD is a neoplastic disease.
A hematologic multidisciplinary oral chemotherapy clinic established at a community hospital identified adverse events early and reduced ED visits.
Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.
Treatment with the multityrosine kinase inhibitor pacritinib resulted in a significant reduction in spleen volume compared with best available therapy, including ruxolitinib, in patients with myelofibrosis and thrombocytopenia, according to a study presented at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition. For the phase 3 PERSIST-2 study (ClinicalTrials.gov identifier: NCT02055781), investigators…
Rescue therapy with pomalidomide in combination with dexamethasone is a rapidly active regimen in amyloid light-chain (AL) amyloidosis.